{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:52:43Z","timestamp":1792507963084,"version":"4.5.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008486","name":"Schweizerische Multiple Sklerose Gesellschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008486","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.lpm.2021.104068","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T04:19:08Z","timestamp":1621829948000},"page":"104068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Update on treatment in multiple sclerosis"],"prefix":"10.1016","volume":"50","author":[{"given":"Ilaria","family":"Callegari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Derfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2021.104068_bib0750","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Wallin","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib0755","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a032003","article-title":"Interferon \u03b2 for multiple sclerosis","volume":"8","author":"Jakimovski","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.lpm.2021.104068_bib0760","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","article-title":"The mechanism of action of interferon-\u03b2 in relapsing multiple sclerosis","volume":"25","author":"Kieseier","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.lpm.2021.104068_bib0765","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo- controlled trial","volume":"43","author":"Duquette","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib0770","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib0775","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1212\/WNL.0b013e3182535cf6","article-title":"Survival in MS A randomized cohort study 21 years after the start of the pivotal IFN\u03b2-1b trial","volume":"78","author":"Goodin","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib0780","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1191\/1352458504ms1007oa","article-title":"Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes","volume":"10","author":"Tremlett","year":"2004","journal-title":"Mult Scler"},{"key":"10.1016\/j.lpm.2021.104068_bib0785","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1316118","article-title":"Thrombotic microangiopathy associated with interferon beta","volume":"370","author":"Hunt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104068_bib0790","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2016-05-715987","article-title":"Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature","volume":"128","author":"Kavanagh","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2021.104068_bib0795","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1212\/01.wnl.0000171858.82527.4c","article-title":"Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis","volume":"65","author":"Ekstein","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib0800","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S1474-4422(10)70103-4","article-title":"Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis","volume":"9","author":"Polman","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib0805","doi-asserted-by":"crossref","first-page":"14593","DOI":"10.1073\/pnas.0404887101","article-title":"Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications","volume":"101","author":"Arnon","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lpm.2021.104068_bib0810","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jamaneurol.2015.2154","article-title":"Equivalence of generic glatiramer acetate in multiple sclerosis: a randomized clinical trial","volume":"72","author":"Cohen","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib0815","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib0820","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.23938","article-title":"Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis","volume":"73","author":"Khan","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib0825","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1474-4422(19)30391-6","article-title":"Advances in oral immunomodulating therapies in relapsing multiple sclerosis","volume":"19","author":"Derfuss","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib0830","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41591-019-0521-4","article-title":"GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis","volume":"25","author":"Galli","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.lpm.2021.104068_bib0835","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaut.2017.09.009","article-title":"Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis","volume":"86","author":"Diebold","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.lpm.2021.104068_bib0840","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1586\/14737175.2015.1025755","article-title":"Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety","volume":"15","author":"Dubey","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.lpm.2021.104068_bib0845","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104068_bib0850","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104068_bib0855","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1352458516649037","article-title":"Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study","volume":"23","author":"Gold","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.lpm.2021.104068_bib0860","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286420915005","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years\u2019 follow-up of DEFINE, CONFIRM, and ENDORSE","volume":"13","author":"Gold","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"issue":"16","key":"10.1016\/j.lpm.2021.104068_bib0865","doi-asserted-by":"crossref","first-page":"P3.061","DOI":"10.1212\/WNL.86.16_supplement.P3.061","article-title":"Rate of brain volume loss with long-term delayed-release dimethyl fumarate treatment in patients with relapsing-remitting multiple sclerosis: 6-year results from ENDORSE (P3.061)","volume":"86","author":"Kappos","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib0870","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.msard.2017.01.006","article-title":"Classifying PML risk with disease modifying therapies","volume":"12","author":"Berger","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.lpm.2021.104068_bib0875","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1177\/1352458519852100","article-title":"A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence","volume":"25","author":"Diebold","year":"2019","journal-title":"Mult Scler J"},{"key":"10.1016\/j.lpm.2021.104068_bib0880","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","article-title":"Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing\u00a0\u2013\u00a0remitting multiple sclerosis: results from the randomized, double-blind. Phase III EVOLVE-MS-2 Study","volume":"34","author":"Naismith","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.lpm.2021.104068_bib0885","doi-asserted-by":"crossref","first-page":"102335","DOI":"10.1016\/j.msard.2020.102335","article-title":"Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate","volume":"45","author":"Wynn","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.lpm.2021.104068_bib0890","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanism of action in multiple sclerosis","volume":"74","author":"Bar-Or","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.lpm.2021.104068_bib0895","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/art.21255","article-title":"Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation","volume":"52","author":"Zeyda","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2021.104068_bib0900","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O\u2019Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104068_bib0905","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib0910","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/cei.12206","article-title":"Requirement for safety monitoring for approved multiple sclerosis therapies: an overview","volume":"175","author":"Rommer","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.lpm.2021.104068_bib0915","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev-immunol-020711-075011","article-title":"Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs","volume":"30","author":"Cyster","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.lpm.2021.104068_bib0920","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1096\/fj.05-3730fje","article-title":"Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P 4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration","volume":"19","author":"Wang","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.lpm.2021.104068_bib0925","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104068_bib0930","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib0935","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104068_bib0940","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","article-title":"Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis","volume":"379","author":"Chitnis","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2021.104068_bib0945","first-page":"1","article-title":"Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML","volume":"8","author":"Fischer-Barnicol","year":"2021","journal-title":"Clinical\/Scientific notes Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib0950","unstructured":"CHMP, \u201cANNEX I SUMMARY OF PRODUCT CHARACTERISTICS.\u201d."},{"key":"10.1016\/j.lpm.2021.104068_bib0955","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jneuroim.2015.05.012","article-title":"Safety and efficacy of reduced fingolimod dosage treatment","volume":"285","author":"Yamout","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.lpm.2021.104068_bib0960","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1352458517694089","article-title":"Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: observational study","volume":"24","author":"Zecca","year":"2018","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.lpm.2021.104068_bib0965","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000874","article-title":"Lymphocyte recovery after fingolimod discontinuation in patients with MS","volume":"7","author":"Nagy","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.lpm.2021.104068_bib0970","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","article-title":"The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate","volume":"167","author":"Gergely","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.lpm.2021.104068_bib0975","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2021.104068_bib0980","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S1474-4422(13)70102-9","article-title":"Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study","volume":"12","author":"Selmaj","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib0985","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/cpt.1547","article-title":"Prediction of the impact of cytochrome P450 2C9 genotypes on the drug\u00a0\u2013\u00a0drug interaction potential of siponimod with physiologically-based pharmacokinetic modeling: a comprehensive approach for drug label recommendations","volume":"106","author":"Huth","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.lpm.2021.104068_bib0990","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-020-01319-7","article-title":"Ozanimod: first approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.lpm.2021.104068_bib0995","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1474-4422(16)00018-1","article-title":"Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Cohen","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1000","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1005","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1010","series-title":"\u201cSpecific Toxicity of 2-Chlorodeoxyadenosine Toward Resting and Proliferating Human Lymphocytes\u201d","author":"Carson","year":"1983"},{"key":"10.1016\/j.lpm.2021.104068_bib1015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(94)91046-4","article-title":"Cladribine in treatment of chronic progressive multiple sclerosis","volume":"344","author":"Sipe","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2021.104068_bib1020","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104068_bib1025","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104068_bib1030","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104068_bib1035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clineuro.2016.07.001","article-title":"Effectiveness and safety of natalizumab in real-world clinical practice: review of observational studies","volume":"149","author":"van Pesch","year":"2016","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.lpm.2021.104068_bib1040","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","article-title":"Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)","volume":"91","author":"Butzkueven","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.lpm.2021.104068_bib1045","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib1050","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib1055","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorensen","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1060","doi-asserted-by":"crossref","first-page":"e00671","DOI":"10.1002\/brb3.671","article-title":"Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation","volume":"7","author":"Gonz\u00e1lez-Suarez","year":"2017","journal-title":"Brain Behav"},{"key":"10.1016\/j.lpm.2021.104068_bib1065","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1352458516641775","article-title":"Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal","volume":"23","author":"Larochelle","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.lpm.2021.104068_bib1070","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1586\/14737175.2016.1168295","article-title":"Disease activity return after natalizumab cessation in multiple sclerosis","volume":"16","author":"Rasenack","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.lpm.2021.104068_bib1075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1212\/WNL.0000000000001706","article-title":"Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS","volume":"85","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib1080","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.msard.2018.07.005","article-title":"Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis","volume":"25","author":"Naegelin","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.lpm.2021.104068_bib1085","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.lpm.2021.104068_bib1090","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104068_bib1095","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104068_bib1100","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104068_bib1105","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104068_bib1110","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.08.011","article-title":"Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis","volume":"175","author":"Jelcic","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.lpm.2021.104068_bib1115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000943","article-title":"Mass cytometry of CSF identifies an MS-associated B-cell population","volume":"8","author":"Johansson","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.lpm.2021.104068_bib1120","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1352458517740641","article-title":"Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study","volume":"25","author":"Agius","year":"2019","journal-title":"Mult Scler J"},{"key":"10.1016\/j.lpm.2021.104068_bib1125","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1130","unstructured":"Abstract: Ocrelizumab Efficacy in PPMS Patients in the Presence\/Absence of T1 Gadolinium-Enhancing Lesions at Baseline in a Phase III, Placebo-Controlled Trial.(2016 CMSC Annual Meeting)."},{"key":"10.1016\/j.lpm.2021.104068_bib1135","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000807","article-title":"Ocrelizumab shorter infusion: primary results from the ENSEMBLE PLUS substudy in patients with MS","volume":"7","author":"Hartung","year":"2020","journal-title":"Neurol Neuroimmunol neuroinflammation"},{"key":"10.1016\/j.lpm.2021.104068_bib1140","first-page":"264","article-title":"Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis","volume":"26","author":"Hauser","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.lpm.2021.104068_bib1145","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/1352458518775550","article-title":"Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients","volume":"24","author":"Mills","year":"2018","journal-title":"Mult Scler J"},{"key":"10.1016\/j.lpm.2021.104068_bib1150","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.lpm.2021.104068_bib1155","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.3390\/ijms160716414","article-title":"Alemtuzumab in multiple sclerosis: mechanism of action and beyond","volume":"16","author":"Ruck","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.lpm.2021.104068_bib1160","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2021.104068_bib1165","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1170","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1212\/NXI.0000000000000868","article-title":"Mitigating alemtuzumab-associated autoimmunity in MS: A \u201cwhack-a-mole\u201d B-cell depletion strategy","volume":"7","author":"Meltzer","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.lpm.2021.104068_bib1175","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.msard.2019.06.022","article-title":"Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis","volume":"34","author":"Romba","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.lpm.2021.104068_bib1180","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/1352458519828663","article-title":"Spontaneous multiple cervical artery dissections after alemtuzumab","volume":"26","author":"Durand-Dubief","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.lpm.2021.104068_bib1185","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.lpm.2021.104068_bib1190","doi-asserted-by":"crossref","first-page":"P3.414","DOI":"10.1212\/WNL.90.15_supplement.P3.414","article-title":"Efficacy and safety of mitoxantrone use in aggressive multiple sclerosis (P3.414)","volume":"90","author":"Fabis-Pedrini","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib1195","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib1200","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1212\/01.WNL.0000095425.84407.39","article-title":"The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"61","author":"Goodin","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib1205","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrneurol.2017.81","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis","volume":"13","author":"Muraro","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1210","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1212\/WNL.0000000000001329","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis","volume":"84","author":"Mancardi","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib1215","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1212\/WNL.0000000000003660","article-title":"High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS","volume":"88","author":"Nash","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib1220","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial","volume":"321","author":"Burt","year":"2019","journal-title":"JAMA\u00a0\u2013\u00a0J Am Med Assoc"},{"key":"10.1016\/j.lpm.2021.104068_bib1225","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bbmt.2019.02.014","article-title":"Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the American Society for Blood and Marrow Transplantation","volume":"25","author":"Cohen","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.lpm.2021.104068_bib1230","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/jnnp-2017-317509","article-title":"Time matters in multiple sclerosis: Can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?","volume":"89","author":"Cerqueira","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.lpm.2021.104068_bib1235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756285614560733","article-title":"Towards the implementation of \u201cno evidence of disease activity\u201d in multiple sclerosis treatment: The multiple sclerosis decision model","volume":"8","author":"Stangel","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.lpm.2021.104068_bib1240","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/1352458518768433","article-title":"Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing\u00a0\u2013\u00a0remitting multiple sclerosis","volume":"24","author":"Lorscheider","year":"2018","journal-title":"Mult Scler J"},{"key":"10.1016\/j.lpm.2021.104068_bib1245","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s00415-018-9126-y","article-title":"Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy","volume":"266","author":"Chalmer","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1250","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.autrev.2017.04.010","article-title":"Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review","volume":"16","author":"Merkel","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.lpm.2021.104068_bib1255","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA\u00a0-\u00a0J Am Med Assoc"},{"key":"10.1016\/j.lpm.2021.104068_bib1260","unstructured":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial -\u00a0Full Text View\u00a0- ClinicalTrials.gov."},{"key":"10.1016\/j.lpm.2021.104068_bib1265","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing\u00a0\u2013\u00a0remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult Scler J"},{"key":"10.1016\/j.lpm.2021.104068_bib1270","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","article-title":"Alemtuzumab CARE-MS i 5-year follow-up: durable efficacy in the absence of continuous MS therapy","volume":"89","author":"Havrdova","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib1275","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib1280","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/1352458509104591","article-title":"Measures in the first year of therapy predict the response to interferon \u03b2 in MS","volume":"15","author":"R\u00edo","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.lpm.2021.104068_bib1285","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.msard.2012.12.001","article-title":"Editors\u2019 welcome and a working definition for a multiple sclerosis cure","volume":"2","author":"Banwell","year":"2013","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.lpm.2021.104068_bib1290","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1352458515616701","article-title":"Inclusion of brain volume loss in a revised measure of \u201cno evidence of disease activity\u201d (NEDA-4) in relapsing-remitting multiple sclerosis","volume":"22","author":"Kappos","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.lpm.2021.104068_bib1295","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/1352458517703193","article-title":"\u201cNo evident disease activity\u201d: the use of combined assessments in the management of patients with multiple sclerosis","volume":"23","author":"Giovannoni","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.lpm.2021.104068_bib1300","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1305","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/1352458513507821","article-title":"Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial","volume":"20","author":"Vermersch","year":"2014","journal-title":"Mult Scler J"},{"key":"10.1016\/j.lpm.2021.104068_bib1310","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2021.104068_bib1315","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1177\/1352458516650736","article-title":"Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies","volume":"22","author":"Baroncini","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.lpm.2021.104068_bib1320","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/ene.13936","article-title":"Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis","volume":"26","author":"Boremalm","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1325","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1468-1331.2008.02071.x","article-title":"Therapeutic outcome 3\u00a0years after switching of immunomodulatory therapies in patients with relapsing\u00a0\u2013\u00a0remitting multiple sclerosis in Argentina","volume":"15","author":"Carr\u00e1","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1330","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1468-1331.2006.01273.x","article-title":"Clinical course after change of immunomodulating therapy in relapsing\u00a0\u2013\u00a0remitting multiple sclerosis","volume":"13","author":"Caon","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1335","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1352458508096687","article-title":"Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis","volume":"15","author":"Gajofatto","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.lpm.2021.104068_bib1340","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2017.00577","article-title":"Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments","volume":"8","author":"Weideman","year":"2017","journal-title":"Front Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1350","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40266-019-00741-1","article-title":"Informing medication discontinuation decisions among older adults with relapsing-onset multiple sclerosis","volume":"37","author":"Schwehr","year":"2020","journal-title":"Drugs Aging"},{"key":"10.1016\/j.lpm.2021.104068_bib1355","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/jnnp-2016-313760","article-title":"Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study","volume":"87","author":"Kister","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.lpm.2021.104068_bib1360","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1083\/jcb.66.2.351","article-title":"The slow component of axonal transport: identification of major structural polypeptides of the axon and their generality among mammalian neurons","volume":"66","author":"Hoffman","year":"1975","journal-title":"J Cell Biol"},{"key":"10.1016\/j.lpm.2021.104068_bib1365","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1523\/JNEUROSCI.1081-12.2012","article-title":"Peripherin is a subunit of peripheral nerve neurofilaments: Implications for differential vulnerability of cns and peripheral nervous system axons","volume":"32","author":"Yuan","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.lpm.2021.104068_bib1370","doi-asserted-by":"crossref","first-page":"10006","DOI":"10.1523\/JNEUROSCI.2580-06.2006","article-title":"\u03b1-internexin is structurally and functionally associated with the neurofilament triplet proteins in the mature CNS","volume":"26","author":"Yuan","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.lpm.2021.104068_bib1375","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/2211068215589580","article-title":"The Simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing","volume":"21","author":"Wilson","year":"2016","journal-title":"J Lab Autom"},{"key":"10.1016\/j.lpm.2021.104068_bib1380","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1385","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.lpm.2021.104068_bib1390","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/WNL.0000000000003653","article-title":"Serum neurofilament is associated with progression of brain atrophy and disability in early MS","volume":"88","author":"Kuhle","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib1395","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1212\/WNL.0000000000001491","article-title":"Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis","volume":"84","author":"Kuhle","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2021.104068_bib1400","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/ana.22247","article-title":"Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab","volume":"69","author":"Gunnarsson","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1405","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1352458513490544","article-title":"Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis","volume":"20","author":"Axelsson","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.lpm.2021.104068_bib1410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000555","article-title":"Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS","volume":"6","author":"Akg\u00fcn","year":"2019","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"key":"10.1016\/j.lpm.2021.104068_bib1415","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/brain\/awh680","article-title":"Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment","volume":"129","author":"Krumbholz","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.lpm.2021.104068_bib1420","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/1352458510389102","article-title":"Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course","volume":"17","author":"Khademi","year":"2011","journal-title":"Mult Scler J"},{"key":"10.1016\/j.lpm.2021.104068_bib1425","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/1352458516639384","article-title":"Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis","volume":"23","author":"Novakova","year":"2017","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.lpm.2021.104068_bib1430","first-page":"341","volume":"41","author":"Meyer Zu H\u00f6rste","year":"2020","journal-title":"Next-generation neuroimmunology: new technologies to understand central nervous system autoimmunity"},{"key":"10.1016\/j.lpm.2021.104068_bib1435","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/eji.201847758","article-title":"The end of omics? High dimensional single cell analysis in precision medicine","volume":"49","author":"Galli","year":"2019","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.lpm.2021.104068_bib1440","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1756285616631897","article-title":"Management of women with multiple sclerosis through pregnancy and after childbirth","volume":"9","author":"Coyle","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.lpm.2021.104068_bib1445","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000367640","article-title":"Pregnancy in multiple sclerosis","volume":"72","author":"Hellwig","year":"2014","journal-title":"Eur Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1450","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.msard.2017.12.001","article-title":"Plasma exchange in severe acute relapses of multiple sclerosis\u00a0\u2013\u00a0results from a Portuguese cohort","volume":"19","author":"Correia","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.lpm.2021.104068_bib1455","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/jca.21468","article-title":"Therapeutic plasma exchange and pregnancy: a case report and guidelines for performing plasma exchange in a pregnant patient","volume":"32","author":"Cox","year":"2017","journal-title":"J Clin Apher"},{"key":"10.1016\/j.lpm.2021.104068_bib1460","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1177\/1352458517731913","article-title":"Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis","volume":"24","author":"Meinl","year":"2018","journal-title":"Mult Scler J"},{"key":"10.1016\/j.lpm.2021.104068_bib1465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000377","article-title":"Dramatic rebounds of MS during pregnancy following fingolimod withdrawal","volume":"4","author":"Novi","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.lpm.2021.104068_bib1470","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaneurol.2014.209","article-title":"Natalizumab use during the third trimester of pregnancy","volume":"71","author":"Haghikia","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000566","article-title":"Different MRI patterns in MS worsening after stopping fingolimod","volume":"6","author":"Lapucci","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.lpm.2021.104068_bib1480","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","article-title":"Rituximab before and during pregnancy","volume":"5","author":"Das","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.lpm.2021.104068_bib1485","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2015.1806","article-title":"Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses","volume":"72","author":"Hellwig","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lpm.2021.104068_bib1490","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/nu3040442","article-title":"Perspectives on immunoglobulins in colostrum and milk","volume":"3","author":"Hurley","year":"2011","journal-title":"Nutrients"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498221000075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498221000075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:07:04Z","timestamp":1760105224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498221000075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":149,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0755498221000075"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2021.104068","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on treatment in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2021.104068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104068"}}